Section 4 of 6
Clinical evidence
251 evidence topics · 39 sources
Study summaries
ORCA-2
Objective
Efficacy and safety objective
Location and study date
U.S. trial dates and site count
| Characteristic | Quoted value |
|---|---|
| Sites | “17”View highlighted excerpt for this quote |
| Start month | “October 2020”View highlighted excerpt for this quote |
| End month | “December 2021”View highlighted excerpt for this quote |
Study design
Eligibility criteria
Smoking eligibility threshold
| Characteristic | Quoted value |
|---|---|
| Minimum cigarettes per day | “10”View highlighted excerpt for this quote |
Treatment
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary abstinence endpoint
| Characteristic | Quoted value |
|---|---|
| Verification method | “biochemically verified” |
| Primary assessment period | “last 4 weeks of treatment” |
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size and power
| Characteristic | Quoted value |
|---|---|
| Planned participants | “750”View highlighted excerpt for this quote |
| Planned power | “96%”View highlighted excerpt for this quote |
| Randomized participants | “810”View highlighted excerpt for this quote |
| Safety population | “809”View highlighted excerpt for this quote |
Description of analysis sets
Primary analysis population and multiplicity
| Characteristic | Quoted value |
|---|---|
| Analysis of all randomized participants: multiplicity adjustment | “Hochberg procedure”View highlighted excerpt for this quote |
Results
Participant disposition
Trial completion
| Characteristic | Quoted value |
|---|---|
| Participants completing follow-up | “618 (76.3%)”View highlighted excerpt for this quote |
Baseline characteristics
Baseline characteristics
| Characteristic | Quoted value |
|---|---|
| Mean age, years | “52.5”View highlighted excerpt for this quote |
| Female participants | “54.6%”View highlighted excerpt for this quote |
| Mean cigarettes per day | “19.4”View highlighted excerpt for this quote |
Efficacy results
Biochemically confirmed continuous smoking abstinence
Sponsor-reported pooled COPD subgroup findings
Number needed to treat at 24 weeks
“At 24 weeks, this new regimen produced 1 additional person abstinent for every 6 people treated with cytisinicline for 12 weeks or for every 11 people treated for 6 weeks” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Participants in the cytisinicline groups had 6- to 8-fold higher odds of continuous smoking abstinence at the end of treatment than participants receiving placebo plus behavioral support.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The efficacy of cytisinicline treatment for both 6 and 12 weeks, compared with placebo, was sustained to 24-week follow-up and was consistently demonstrated in subgroups defined by baseline characteristics.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Cigarette craving on the Brief Questionnaire of Smoking Urges
“To assess cigarette craving between groups, the Brief Questionnaire of Smoking Urges (QSU-brief) was administered at clinic visits on day 0 and at weeks 1 to 6.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mean total cigarette craving score, using the QSU-brief, declined more rapidly between baseline and week 6 among participants who received cytisinicline for 6 or 12 weeks compared with placebo” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Confidence intervals for the effect estimates at weeks 1 to 6 excluded 0, providing evidence of a rapid and sustained effect.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Safety results
Treatment-related serious adverse events
Study limitations
Summary
The comparator was placebo rather than another cessation medication. The primary endpoint assessed abstinence near the end of treatment; follow-up extended to week 24. The trial therefore does not establish comparative effectiveness against active medication or durability beyond 24 weeks.
ORCA-3
Objective
Efficacy and safety objective
Location and study date
Study design
Eligibility criteria
Smoking eligibility threshold
| Characteristic | Quoted value |
|---|---|
| Minimum cigarettes smoked daily | “10”View highlighted excerpt for this quote |
Treatment
Concomitant behavioral intervention
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Biochemical verification of abstinence
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size and statistical power
| Characteristic | Quoted value |
|---|---|
| Planned participants | “750”View highlighted excerpt for this quote |
| Power | “96%”View highlighted excerpt for this quote |
| Randomized participants | “792”View highlighted excerpt for this quote |
| Safety-analysis participants | “785”View highlighted excerpt for this quote |
Description of analysis sets
Primary analysis and multiplicity
| Characteristic | Quoted value |
|---|---|
| Efficacy analysis principle | “intent-to-treat”View highlighted excerpt for this quote |
| Multiplicity procedure | “Hochberg procedure”View highlighted excerpt for this quote |
| Classification of missed assessments | “still smoking”View highlighted excerpt for this quote |
Results
Participant disposition
Completion at week 24
| Characteristic | Quoted value |
|---|---|
| Participants completing the trial | “628”View highlighted excerpt for this quote |
| Completion percentage | “79.3%”View highlighted excerpt for this quote |
Baseline characteristics
Baseline age and sex
| Characteristic | Quoted value |
|---|---|
| Mean age, years | “52.0”View highlighted excerpt for this quote |
| Female participants | “55.4%”View highlighted excerpt for this quote |
Efficacy results
Biochemically confirmed smoking cessation
Health-related quality of life and patient-reported outcomes
Change in smoking-urge score at week 6
| Characteristic | Quoted value |
|---|---|
| Cytisinicline, mean change in points | “−15.2”View highlighted excerpt for this quote |
| Placebo, mean change in points | “−12.0”View highlighted excerpt for this quote |
Safety results
Adverse events: placebo, 6-week cytisinicline, 12-week cytisinicline
“Insomnia: (7.6%, 11.0%, 11.9%)” (opens the source at this quote in a new tab)
“Abnormal dreams: (5.7%, 9.1%, 7.7%)” (opens the source at this quote in a new tab)
“Nausea (7.3%, 9.5%, 6.9%)” (opens the source at this quote in a new tab)
“Headache (6.1%, 7.6%, 8.5%)” (opens the source at this quote in a new tab)
Study limitations
Summary
The study replicated placebo-controlled findings but did not compare cytisinicline with an active cessation medication. Of 792 randomized participants, 628 completed the trial. Follow-up through week 24 does not establish longer-term abstinence or safety.
ORCA-OL
Objective
Extended exposure objective
Location and study date
U.S. study sites
| Characteristic | Quoted value |
|---|---|
| Number of U.S. sites | “29” |
Study design
Eligibility criteria
Prior-study eligibility
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary safety endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Treated participants
| Characteristic | Quoted value |
|---|---|
| Treated sample | “475” |
Description of analysis sets
Safety analysis set
Results
Participant disposition
Exposure duration
| Characteristic | Quoted value |
|---|---|
| Participants exposed for at least 24 weeks, number and percentage | “392 (82.5)” |
| Participants exposed for at least 48 weeks, number and percentage | “319 (67.2)” |
| Participants exposed for at least 51 weeks, number and percentage | “281 (59.2)” |
Baseline characteristics
Baseline age and sex
| Characteristic | Quoted value |
|---|---|
| Median age, years | “55” |
| Female participants, number and percentage | “275 (57.9)” |
Efficacy results
Not applicable.
Health-related quality of life and patient-reported outcomes
Safety results
Serious adverse events, deaths, and discontinuations
Study limitations
Summary
This open-label study had no concurrent comparator. It enrolled participants previously treated in the ORCA program, rather than a newly recruited randomized population. Exposure declined from 475 treated participants to 281 with at least 51 weeks of treatment. The exit survey was voluntary.
ORCA-1
Objective
Dose and schedule selection
Location and study date
Trial period
| Characteristic | Quoted value |
|---|---|
| First visit date | “20 November 2018”View highlighted excerpt for this quote |
| Completion date | “23 April 2019”View highlighted excerpt for this quote |
Study design
Eligibility criteria
Cigarette-use eligibility
| Characteristic | Quoted value |
|---|---|
| Baseline daily cigarette threshold | “>10”View highlighted excerpt for this quote |
Treatment
Cytisinicline dose levels
| Characteristic | Quoted value |
|---|---|
| Lower tablet dose | “1.5 mg”View highlighted excerpt for this quote |
| Higher tablet dose | “3 mg”View highlighted excerpt for this quote |
Study outcomes
Rationale for using percentage of expected cigarettes smoked as the primary endpoint
Secondary week-4 abstinence definition
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized participants
| Characteristic | Quoted value |
|---|---|
| Total randomized | “254”View highlighted excerpt for this quote |
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Baseline age and smoking
| Characteristic | Quoted value |
|---|---|
| Mean age, years | “48.4”View highlighted excerpt for this quote |
| Mean cigarettes per day | “18.2”View highlighted excerpt for this quote |
Efficacy results
Cytisinicline 3 mg three times daily versus placebo
| Outcome | Cytisinicline | Placebo | P value |
|---|---|---|---|
| Four-week abstinence | “50%” | “10%” | “p < 0.001” |
| Continuous abstinence, weeks 5–8 | “30%” | “8%” | “p = 0.005” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Serious and severe adverse events
Study limitations
Summary
The primary endpoint measured cigarette reduction, not sustained smoking cessation. The table’s four-week abstinence label refers to seven-day point-prevalence abstinence at the end of treatment, not four weeks of continuous abstinence. Continuous abstinence was evaluated separately during weeks 5–8.
ORCA-V1
Objective
Location and study date
Trial period
| Characteristic | Quoted value |
|---|---|
| First month | “July 2022”View highlighted excerpt for this quote |
| Last month | “February 2023”View highlighted excerpt for this quote |
Study design
Blinding and allocation
| Characteristic | Quoted value |
|---|---|
| Blinding | “double-blind”View highlighted excerpt for this quote |
| Allocation | “randomized”View highlighted excerpt for this quote |
Eligibility criteria
Current cigarette-smoking exclusion
Treatment
Dose schedule
| Characteristic | Quoted value |
|---|---|
| Cytisinicline dose, mg | “3”View highlighted excerpt for this quote |
| Daily dosing frequency | “3”View highlighted excerpt for this quote |
| Treatment duration, weeks | “12”View highlighted excerpt for this quote |
Study outcomes
Rationale for using continuous e-cigarette abstinence as the primary endpoint
Primary endpoint assessment
| Characteristic | Quoted value |
|---|---|
| Continuous vaping-abstinence interval, weeks | “9-12”View highlighted excerpt for this quote |
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized participants
| Characteristic | Quoted value |
|---|---|
| Cytisinicline | “107”View highlighted excerpt for this quote |
| Placebo | “53”View highlighted excerpt for this quote |
Description of analysis sets
Classification of missing outcomes
Results
Participant disposition
Trial completion
| Characteristic | Quoted value |
|---|---|
| Participants completing follow-up | “131”View highlighted excerpt for this quote |
Baseline characteristics
Baseline age
| Characteristic | Quoted value |
|---|---|
| Mean age, years | “33.6”View highlighted excerpt for this quote |
Efficacy results
Vaping cessation during weeks 9 to 12
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse-event discontinuations
| Characteristic | Quoted value |
|---|---|
| Participants discontinuing cytisinicline because of an adverse event | “4”View highlighted excerpt for this quote |
Study limitations
Summary
This study enrolled adults who vaped but did not currently smoke cigarettes. It therefore provides supporting evidence for vaping cessation rather than a direct estimate of smoking-cessation efficacy. The investigators called for a larger trial with longer follow-up.
ISRCTN37568749
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Treatment
Treatment and follow-up
| Characteristic | Quoted value |
|---|---|
| Treatment duration | “25 days”View highlighted excerpt for this quote |
| Behavioral intervention | “minimal amount of counseling”View highlighted excerpt for this quote |
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment
| Characteristic | Quoted value |
|---|---|
| Randomized participants | “740”View highlighted excerpt for this quote |
| Participants per treatment group | “370”View highlighted excerpt for this quote |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Sustained 12-month abstinence
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Gastrointestinal adverse events
| Characteristic | Quoted value |
|---|---|
| Absolute excess with cytisine, percentage points | “5.7”View highlighted excerpt for this quote |
Study limitations
Summary
This was a single-center trial with minimal counseling and a 25-day cytisine regimen. Its results do not directly test the 6-week or 12-week, 3 mg three-times-daily regimen evaluated in ORCA-2.
ACTRN12610000590066
Objective
Location and study date
Study design
Eligibility criteria
Quitline population
Treatment
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary outcome
| Characteristic | Quoted value |
|---|---|
| Ascertainment | “self-reported” |
| Continuous-abstinence assessment | “1 month” |
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized participants
| Characteristic | Quoted value |
|---|---|
| Total randomized | “1310” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
Treatment was open-label and the primary outcome was self-reported abstinence at one month. Cytisine and nicotine replacement therapy were given for different durations. These features limit blinding and comparability with trials using biochemical verification as the primary outcome.
NCT02957786
Objective
Comparative objective
Location and study date
Study design
Allocation and masking
Eligibility criteria
Treatment
Treatment duration
| Characteristic | Quoted value |
|---|---|
| Cytisine and varenicline courses | “12 weeks” |
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary outcome timing
| Characteristic | Quoted value |
|---|---|
| Verified continuous-abstinence assessment | “6 months” |
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Missing-data analysis
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
Enrollment was 679 participants compared with a planned 2,140. The open-label design and recruitment below target limit precision and leave potential reporting and performance bias. The population and 12-week cytisine regimen differ from other historical cytisine trials.
ACTRN12616001654448
Objective
Location and study date
Study design
Eligibility criteria
Treatment
Treatment duration
| Characteristic | Quoted value |
|---|---|
| Cytisine, days | “25”View highlighted excerpt for this quote |
| Varenicline, days | “84”View highlighted excerpt for this quote |
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary outcome
| Characteristic | Quoted value |
|---|---|
| Continuous-abstinence assessment | “6 months”View highlighted excerpt for this quote |
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized sample
| Characteristic | Quoted value |
|---|---|
| Total participants | “1452”View highlighted excerpt for this quote |
| Cytisine | “725”View highlighted excerpt for this quote |
| Varenicline | “727”View highlighted excerpt for this quote |
Description of analysis sets
Noninferiority threshold
| Characteristic | Quoted value |
|---|---|
| Margin | “5%”View highlighted excerpt for this quote |
| One-sided significance level | “.025”View highlighted excerpt for this quote |
Results
Participant disposition
Follow-up completion
| Characteristic | Quoted value |
|---|---|
| Participants completing follow-up | “1108”View highlighted excerpt for this quote |
Baseline characteristics
Baseline age and sex
| Characteristic | Quoted value |
|---|---|
| Mean age, years | “42.9”View highlighted excerpt for this quote |
| Female participants | “51.1%”View highlighted excerpt for this quote |
Efficacy results
Verified 6-month continuous abstinence
Risk difference and investigator conclusion
“Verified 6-month continuous abstinence rates were 11.7% for the cytisine group and 13.3% for the varenicline group (risk difference, −1.62% [1-sided 97.5% CI, −5.02% to ∞]; P = .03 for noninferiority).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among daily smokers willing to quit, cytisine treatment for 25 days, compared with varenicline treatment for 84 days, failed to demonstrate noninferiority regarding smoking cessation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Reported adverse-event counts
| Characteristic | Quoted value |
|---|---|
| Cytisine | “997”View highlighted excerpt for this quote |
| Varenicline | “1206”View highlighted excerpt for this quote |
Self-reported adverse events: incident rate ratio against varenicline
“Self-reported adverse events occurred less frequently in the cytisine group (997 events among 482 participants) compared with the varenicline group (1206 events among 510 participants) and the incident rate ratio was 0.88 (95% CI, 0.81 to 0.95; P = .002).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
The primary analysis did not establish noninferiority. Cytisine was administered for 25 days and varenicline for 84 days, so the comparison combines differences in medication and duration. The trial was open-label.
ISRCTN43811467
Objective
Location and study date
Study design
Eligibility criteria
Treatment
Regimen
| Characteristic | Quoted value |
|---|---|
| Treatment course | “25 days”View highlighted excerpt for this quote |
| Concomitant intervention | “brief behavioural support”View highlighted excerpt for this quote |
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary assessment
| Characteristic | Quoted value |
|---|---|
| Continuous-abstinence follow-up, months | “6”View highlighted excerpt for this quote |
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized participants
| Characteristic | Quoted value |
|---|---|
| Total | “2472”View highlighted excerpt for this quote |
| Cytisine | “1239”View highlighted excerpt for this quote |
| Placebo | “1233”View highlighted excerpt for this quote |
Description of analysis sets
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Continuous abstinence at 6 months
| Characteristic | Quoted value |
|---|---|
| Cytisine participants abstinent | “401”View highlighted excerpt for this quote |
| Placebo participants abstinent | “366”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Participants with serious adverse events
| Characteristic | Quoted value |
|---|---|
| Cytisine | “53”View highlighted excerpt for this quote |
| Placebo | “46”View highlighted excerpt for this quote |
Study limitations
Summary
The study population had pulmonary tuberculosis, and both groups received brief behavioral support. The investigators did not support adding cytisine in this setting. Results should not be treated as a direct evaluation of the ORCA regimen in the general smoking population.
SMILE
Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary outcome
| Characteristic | Quoted value |
|---|---|
| Continuous-abstinence assessment | “12 months”View highlighted excerpt for this quote |
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized population
| Characteristic | Quoted value |
|---|---|
| Total | “869”View highlighted excerpt for this quote |
| Cytisine plus counseling | “470”View highlighted excerpt for this quote |
| Counseling alone | “399”View highlighted excerpt for this quote |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Biochemically verified continuous abstinence
| Characteristic | Quoted value |
|---|---|
| Cytisine plus counseling | “32.1%”View highlighted excerpt for this quote |
| Counseling alone | “7.3%”View highlighted excerpt for this quote |
| Adjusted odds ratio | “7.2”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Participants reporting adverse events
| Characteristic | Quoted value |
|---|---|
| Cytisine group | “196”View highlighted excerpt for this quote |
| Control group | “133”View highlighted excerpt for this quote |
Study limitations
Summary
This single-center trial enrolled current heavy smokers in lung-cancer screening. Its control was counseling alone rather than placebo tablets or an active cessation medication. Applicability to other smoking populations and comparative tolerability against active medication remain uncertain.
TCTR20180312001
Objective
Location and study date
Study design
Eligibility criteria
Eligibility thresholds
| Characteristic | Quoted value |
|---|---|
| Age, years | “>18”View highlighted excerpt for this quote |
| Daily tobacco consumption | “>10 tobaccos/day”View highlighted excerpt for this quote |
Treatment
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Primary endpoint
| Characteristic | Quoted value |
|---|---|
| Continuous-abstinence assessment | “week 48”View highlighted excerpt for this quote |
Statistical analysis description
Number of participants (Planned and analyzed)
Treatment groups
| Characteristic | Quoted value |
|---|---|
| Cytisine participants | “67”View highlighted excerpt for this quote |
| Placebo participants | “65”View highlighted excerpt for this quote |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Week-48 treatment comparison
| Characteristic | Quoted value |
|---|---|
| Relative risk | “2.41”View highlighted excerpt for this quote |
| 95% confidence interval | “0.80-7.35”View highlighted excerpt for this quote |
| P value | “0.102”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
The trial included 67 participants receiving cytisine and 65 receiving placebo. The week-48 relative-risk confidence interval included no difference (relative risk 2.41; 95% confidence interval 0.80–7.35; P = 0.102). The small groups limit precision and assessment of uncommon harms.
Cytisine versus nortriptyline
Objective
Comparative objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse-event characterization
Study limitations
Summary
The observed relative-risk confidence interval, 0.91–1.81, includes no difference. The nonsignificant comparison does not by itself establish equivalence. Cytisine and nortriptyline were administered for different durations.
Cytisine versus varenicline in primary care
Objective
No evidence found.
Location and study date
No evidence found.
Study design
No evidence found.
Eligibility criteria
No evidence found.
Treatment
No evidence found.
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
No evidence found.
NCT04286295
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Treatment
Treatment course
| Characteristic | Quoted value |
|---|---|
| Cytisine or combination nicotine replacement therapy | “25 days”View highlighted excerpt for this quote |
Study outcomes
Rationale for using recruitment and treatment adherence as the primary feasibility endpoints
Statistical analysis description
Number of participants (Planned and analyzed)
Recruitment
| Characteristic | Quoted value |
|---|---|
| Recruited participants | “13”View highlighted excerpt for this quote |
Description of analysis sets
No evidence found.
Results
Participant disposition
Baseline characteristics
No evidence found.
Efficacy results
Participants abstinent at day 25
| Characteristic | Quoted value |
|---|---|
| Cytisine | “1”View highlighted excerpt for this quote |
| Nicotine replacement therapy | “0”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
This pilot recruited 13 participants and nine completed follow-up. It was designed to evaluate recruitment and adherence, not to provide a definitive comparative efficacy estimate. Its end-of-treatment cessation findings are therefore exploratory.
RISP
Objective
No evidence found.
Location and study date
No evidence found.
Study design
No evidence found.
Eligibility criteria
No evidence found.
Treatment
No evidence found.
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
No evidence found.
CITISILONG
Objective
Duration-comparison objective
Location and study date
Study design
Eligibility criteria
Adult eligibility threshold
| Characteristic | Quoted value |
|---|---|
| Minimum age, years | “18” |
Treatment
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Long-term abstinence assessments
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Planned analysis set
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
The report contains a protocol, not observed cessation or safety results. Planned comparisons are open-label and use 25-, 50-, and 75-day courses. The clinically evaluable analysis population may differ from all randomized participants.
Forty-day cytisine regimen
Objective
Location and study date
Study period and country
| Characteristic | Quoted value |
|---|---|
| Observation period | “2015–2021”View highlighted excerpt for this quote |
| Country | “Italy”View highlighted excerpt for this quote |
Study design
Eligibility criteria
Treatment
Compared treatment durations
| Characteristic | Quoted value |
|---|---|
| Cytisine | “40 days”View highlighted excerpt for this quote |
| Varenicline | “12 weeks”View highlighted excerpt for this quote |
| Nicotine replacement therapy | “eight weeks”View highlighted excerpt for this quote |
Study outcomes
Rationale for using biochemically confirmed smoking abstinence as a study endpoint
Abstinence assessment
| Characteristic | Quoted value |
|---|---|
| Follow-up interval | “6 months”View highlighted excerpt for this quote |
Statistical analysis description
Number of participants (Planned and analyzed)
Treatment cohorts
| Characteristic | Quoted value |
|---|---|
| Cytisine | “543”View highlighted excerpt for this quote |
| Varenicline | “281”View highlighted excerpt for this quote |
| Nicotine replacement therapy | “47”View highlighted excerpt for this quote |
Description of analysis sets
Continuous-variable comparison
Results
Participant disposition
No evidence found.
Baseline characteristics
Cytisine group at baseline
| Characteristic | Quoted value |
|---|---|
| Mean age, years | “52.5”View highlighted excerpt for this quote |
Efficacy results
Biochemically confirmed smoking abstinence
| Characteristic | Quoted value |
|---|---|
| Cytisine | “50.5%”View highlighted excerpt for this quote |
| Varenicline | “55.9%”View highlighted excerpt for this quote |
| Nicotine replacement therapy | “51.0%”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Cytisine adverse events
| Characteristic | Quoted value |
|---|---|
| Participants reporting an adverse event | “24”View highlighted excerpt for this quote |
| Percentage | “4.4%”View highlighted excerpt for this quote |
Study limitations
Summary
Allocation was not randomized, and there was no placebo group or direct comparison with the standard 25-day cytisine regimen. The observed differences cannot establish that extending treatment to 40 days caused improved outcomes.
CITOSP
Objective
Clinical safety objective
Location and study date
Study design
Observational design
Eligibility criteria
Cardiology population
Treatment
Study outcomes
Rationale for using adverse drug reactions as the primary safety endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Enrolled participants
| Characteristic | Quoted value |
|---|---|
| Cohort size | “36” |
Description of analysis sets
Minimum exposure for analysis
Results
Participant disposition
Study completion
| Characteristic | Quoted value |
|---|---|
| Participants completing the study | “22 (61.1%)” |
Baseline characteristics
Baseline sex
| Characteristic | Quoted value |
|---|---|
| Male participants | “83.3%” |
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
The evidence comes from a prospective observational cohort of 36 hospitalized smokers with cardiovascular disease. Its small size and lack of randomized comparison limit causal interpretation and assessment of uncommon cardiovascular harms. The reported longitudinal cessation percentages are self-reported outcomes.
Retrospective comparative-effectiveness cohort
Objective
Clinical objective
Location and study date
Study design
Eligibility criteria
Adult eligibility
| Characteristic | Quoted value |
|---|---|
| Minimum age, years | “18” |
Treatment
Medication groups
| Characteristic | Quoted value |
|---|---|
| Treatments compared | “cytisine, bupropion, and nicotine replacement therapy” |
Study outcomes
Rationale for using self-reported smoking abstinence as a study endpoint
Abstinence ascertainment
Statistical analysis description
Number of participants (Planned and analyzed)
Analyzed participants
| Characteristic | Quoted value |
|---|---|
| Total cohort | “113” |
Description of analysis sets
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Treatment adherence and outcome
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
Treatment selection reflected routine practice rather than randomization, and multivariable modeling was not performed. The association between adherence and cessation does not establish a causal medication effect or an adjusted comparative treatment effect.
DESTINA
Objective
No evidence found.
Location and study date
No evidence found.
Study design
No evidence found.
Eligibility criteria
No evidence found.
Treatment
No evidence found.
Study outcomes
Rationale for using patient satisfaction and tolerability as the study outcomes
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
Safety results
No evidence found.
Study limitations
No evidence found.
Placebo-controlled trial in workers
Objective
Clinical objective
Location and study date
No evidence found.
Study design
Blinded randomized design
Eligibility criteria
Occupational population
Treatment
Treatment course
Study outcomes
Rationale for using self-reported continuous abstinence as a study endpoint
Outcome ascertainment
Statistical analysis description
Number of participants (Planned and analyzed)
Randomized participants
| Characteristic | Quoted value |
|---|---|
| Total | “171” |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
No evidence found.
Study limitations
Summary
Abstinence was self-reported. The study enrolled men working in mining, limiting direct applicability to broader clinical populations. It evaluated a 25-day regimen rather than the longer ORCA regimens.
Matching-adjusted indirect comparison
Objective
Comparative objective
Location and study date
Not applicable.
Study design
Indirect comparative design
Eligibility criteria
Comparator population
Treatment
Treatment exposure
| Characteristic | Quoted value |
|---|---|
| Cytisinicline course | “12 weeks” |
Study outcomes
Rationale for using continuous smoking abstinence as the primary endpoint
Abstinence assessment intervals
| Characteristic | Quoted value |
|---|---|
| End of treatment | “Weeks 9-12” |
| Longer follow-up | “Weeks 9-24” |
Statistical analysis description
Number of participants (Planned and analyzed)
Contributing cytisinicline trials
| Characteristic | Quoted value |
|---|---|
| Trials pooled | “ORCA-2 and ORCA-3” |
Description of analysis sets
Adjustment approach
Results
Participant disposition
Not applicable.
Baseline characteristics
No evidence found.
Efficacy results
Adjusted continuous-abstinence estimates
| Assessment | Quoted estimate |
|---|---|
| Continuous abstinence, weeks 9–12 | “adjusted OR, 1.33; 95% CI, 0.86-2.05” |
| Continuous abstinence, weeks 9–24 | “adjusted OR, 1.95; 95% CI, 1.13-3.34” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adjusted nausea estimate
| Assessment | Quoted estimate |
|---|---|
| Nausea | “adjusted OR, 0.18; 95% CI, 0.10-0.31” |
Study limitations
Summary
This is an indirect comparison, not a randomized head-to-head trial. Weighting cannot remove confounding from unmeasured differences between trials. The weeks 9–12 odds-ratio confidence interval includes no difference, while the weeks 9–24 interval does not. These estimates should not be interpreted as head-to-head evidence.
Phase I dose-escalation study
Objective
No evidence found.
Location and study date
No evidence found.
Study design
No evidence found.
Eligibility criteria
No evidence found.
Treatment
No evidence found.
Study outcomes
Rationale for using tolerability and safety as the primary endpoints
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Not applicable.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
No evidence found.
Single-dose pharmacokinetic study
Objective
Pharmacokinetic objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using plasma and urinary cytisine concentrations as the pharmacokinetic endpoints
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
The study characterized a single dose in healthy smokers. It does not establish smoking-cessation efficacy or the safety of repeated administration for 6 or 12 weeks.
ACTRN12613000002785
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Treatment
Regimen duration
| Characteristic | Quoted value |
|---|---|
| Treatment period | “25-day”View highlighted excerpt for this quote |
Study outcomes
Rationale for using plasma cytisine concentrations as the pharmacokinetic endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Participants
| Characteristic | Quoted value |
|---|---|
| Study sample | “10”View highlighted excerpt for this quote |
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
The pharmacokinetic study included 10 healthy adult smokers and used the standard 25-day regimen. It provides evidence of accumulation but cannot establish clinical cessation efficacy or detect uncommon harms.
Ascending-dose pharmacokinetic study
Objective
No evidence found.
Location and study date
No evidence found.
Study design
No evidence found.
Eligibility criteria
No evidence found.
Treatment
No evidence found.
Study outcomes
Rationale for using cytisine pharmacokinetics as the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Not applicable.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
No evidence found.